MedTrace Logo

Study of Oral Administration of Ribavirin and Nitazoxamide Versus Placebo in COVID-19

NCT04563208 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2022-07-14

No results posted yet for this study

Summary

This is a single center, randomized, double-blind, 2-arm, parallel-group study of DuACT in participants with clinical symptoms of COVID-19 that have begun within the past 72 hours prior to testing.

Conditions

  • Covid19
  • SARS-CoV Infection

Interventions

DRUG

Placebo

Placebo administered on Days 1-5

DRUG

DuACT

Day1: RBV 600 mg BID and NTZ 500 mg BID Days 2-5: RBV 400 mg BID and NTZ 500 mg BID

Sponsors & Collaborators

  • SynaVir

    collaborator INDUSTRY

  • University of Witwatersrand, South Africa

    lead OTHER

Principal Investigators

  • Simiso Sokhela · Ezintsha

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-09
Primary Completion
2022-02-28
Completion
2022-02-28

Countries

  • South Africa

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04563208 on ClinicalTrials.gov